Gene therapy for lung cancer

Lung Cancer

Volumn 23, Issue 3, 1999, Pages 191-207

  Frederiksen, Klaus Stensgaard ^a   Petri, Andreas ^a   Abrahamsen, Niels ^a   Poulsen, Hans Skovgaard ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Gene therapy; Lung cancer; Promoters; Receptors; Targeted gene delivery; Vectorology

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROTEIN P53; TRANSCRIPTION FACTOR;

ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE; ONCOGENE C MYC; ONCOGENE MYC; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DNA, ANTISENSE; GENE TARGETING; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; LUNG NEOPLASMS; ONCOGENES; ORGAN SPECIFICITY; PROMOTER REGIONS (GENETICS); RATS; TRANSCRIPTION, GENETIC;

EID: 0032943861     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00012-4     Document Type: Article

References (99)

1. Craven S.A. Georgius Agricola: 1494-1555-mining engineer and physician. S Afr Med J. 87:1997;611-612.
2. Sjolin K.E., Pedersen K.M., Petersen I.C., Thonesen V. Lungekræft. Tobaksproblemet. 1969;82-104 Indenrigsministeriet, Copenhagen.
3. Roth J.A. Molecular events in lung cancer. Lung Cancer. 12(Suppl 2):1995;3-15.
4. Williams C.L. Basic science of small cell lung cancer. Chest Surg Clin N Am. 7:1997;1-19.
5. Hunter T. Oncoprotein networks. Cell. 88:1997;333-346.
6. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL. Neoplasms of the lung. In: Harrison's principles of internal medicine. New York: McGraw-Hill, 1994, pp. 1221-9.
7. Lassen U.N., Hansen H.H. Smacellet lungecancer (Small cell lung cancer). Ugeskr Laeger. 158:1996;4517-4519. in Danish.
8. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
9. Rygaard K., Vindelov L.L., Spang Thomsen M. Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. Int J Cancer. 54:1993;144-152.
10. Takahashi T., Obata Y., Sekido Y., Hida T., Ueda R., Watanabe H. et al. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res. 49:1989;2683-2688.
11. Barr L.F., Campbell S.E., Baylin S.B. Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. Cell Growth Differ. 8:1997;381-392.
12. Kumagai T., Tanio Y., Osaki T., Hosoe S., Tachibana I., Ueno K. et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res. 56:1996;354-358.
13. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
14. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr, Butel J.S. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
15. Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet. 8:1994;66-69.
16. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
17. Donehower L.A., Bradley A. The tumor suppressor p53. Biochim Biophys Acta. 1155:1993;181-205.
18. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
19. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
20. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
21. Cotran R.S., Kumar V., Robbins S.L. Cellular injury and cellular death. In: Robbin's pathologic basis of disease. Philadelphia, PA: Saunders, 1994, pp. 1-34.
22. Fujiwara T., Grimm E.A., Mukhopadhyay T., Cai D.W., Owen Schaub L.B., Roth J.A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53:1993;4129-4133.
23. Hamada K., Alemany R., Zhang W.W., Hittelman W.N., Lotan R., Roth J.A. et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 56:1996;3047-3054.
24. Nguyen D.M., Wiehle S.A., Koch P.E., Branch C., Yen N., Roth J.A. et al. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther. 4:1997;191-198.
25. Hollstein M., Rice K., Greenblatt M.S., Soussi T., Fuchs R., Sorlie T. et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:1994;3551-3555.
26. Culver K.W., Blaese R.M. Gene therapy for cancer. Trends Genet. 10:1994;174-178.
27. Roth J.A., Cristiano R.J. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 89:1997;21-39.
28. Helene C., Toulme J.J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1049:1990;99-125.
29. Dosaka Akita H., Akie K., Hiroumi H., Kinoshita I., Kawakami Y., Murakami A. Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res. 55:1995;1559-1564.
30. Mukhopadhyay T., Tainsky M., Cavender A.C., Roth J.A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 51:1991;1744-1748.
31. Robinson L.A., Smith L.J., Fontaine M.P., Kay H.D., Mountjoy C.P., Pirruccello S.J. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg. 60:1995;1583-1591.
32. Lee C.T., Wu S., Gabrilovich D., Chen H., Nadaf Rahrov S., Ciernik I.F. et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 56:1996;3038-3041.
33. Cochet O., Kenigsberg M., Delumeau I., Virone Oddos A., Multon M.C., Fridman W.H. et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58:1998;1170-1176.
34. Deshane J., Siegal G.P., Wang M., Wright M., Bucy R.P., Alvarez R.D. et al. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol Oncol. 64:1997;378-385.
35. Paul S., Dummer S. Topics in clinical pharmacology: ganciclovir. Am J Med Sci. 304:1992;272-277.
36. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L. et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274-5283.
37. Yang L., Chiang Y., Lenz H.J., Danenberg K.D., Spears C.P., Gordon E.M. et al. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther. 9:1998;719-728.
38. Nielsen L.L., Maneval D.C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5:1998;52-63.
39. Takahashi T., Carbone D., Nau M.M., Hida T., Linnoila I., Ueda R. et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 52:1992;2340-2343.
40. Gavrieli Y., Sherman Y., Ben Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
41. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 2:1996;985-991.
42. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 86:1994;1458-1462.
43. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen Schaub L.B., Roth J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
44. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
45. Roth J.A., Swisher S.G., Merritt J.A., Lawrence D.D., Kemp B.L., Carrasco C.H. et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol. 25:1998;33-37.
46. Spitz F.R., Nguyen D.M., Skibber J.M., Meyn R.E., Cristiano R.J., Roth J.A. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res. 2:1996;1665-1671.
47. Sandig V., Brand K., Herwig S., Lukas J., Bartek J., Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 3:1997;313-319.
48. Lukas J., Parry D., Aagaard L., Mann D.J., Bartkova J., Strauss M. et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 375:1995;503-506.
49. Xu H.J., Zhou Y., Seigne J., Perng G.S., Mixon M., Zhang C. et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 56:1996;2245-2249.
50. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim Biophys Acta. 1113:1992;171-199.
51. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
52. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54:1994;987-992.
53. Markowitz D., Goff S., Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 167:1988;400-406.
54. Mitani K., Caskey C.T. Delivering therapeutic genes-matching approach and application. Trends Biotechnol. 11:1993;162-166.
55. Miller D.G., Adam M.A., Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 10:1990;4239-4242. published erratum appears in Mol Cell Biol 1992;12(1):433.
56. Yoshimura K., Rosenfeld M.A., Seth P., Crystal R.G. Adenovirus-mediated augmentation of cell transfection with unmodified plasmid vectors. J Biol Chem. 268:1993;2300-2303.
57. Gao L., Wagner E., Cotten M., Agarwal S., Harris C., Romer M. et al. Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes. Hum Gene Ther. 4:1993;17-24.
58. Gottschalk S., Sparrow J.T., Hauer J., Mims M.P., Leland F.E., Woo S.L. et al. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther. 3:1996;48-57.
59. Wagner E., Plank C., Zatloukal K., Cotten M., Birnstiel M.L. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci USA. 89:1992;7934-7938.
60. Veale D., Ashcroft T., Marsh C., Gibson G.J., Harris A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 55:1987;513-516.
61. Cristiano R.J., Roth J.A. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther. 3:1996;4-10.
62. Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther 1998.
63. Bergelson J.M., Cunningham J.A., Droguett G., Kurt Jones E.A., Krithivas A., Hong J.S. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1997;1320-1323.
64. Stevenson S.C., Rollence M., White B., Weaver L., McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol. 69:1995;2850-2857.
65. Michael S.I., Huang C.H., Romer M.U., Wagner E., Hu P.C., Curiel D.T. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J Biol Chem. 268:1993;6866-6869.
66. Foster B.J., Kern J.A. HER2-targeted gene transfer. Hum Gene Ther. 8:1997;719-727.
67. Shimizu N., Chen J., Gamou S., Takayanagi A. Immunogene approach toward cancer therapy using epidermal growth factor receptor-mediated gene delivery. Cancer Gene Ther. 3:1996;113-120.
68. Wilson J.M., Grossman M., Wu C.H., Chowdhury N.R., Wu G.Y., Chowdhury J.R. Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J Biol Chem. 267:1992;963-967.
69. Wu C.H., Wilson J.M., Wu G.Y. Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem. 264:1989;16985-16987.
70. Stratford-Perricaudet L.D., Makeh I., Perricaudet M., Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest. 90:1992;626-630.
71. Watkins S.J., Mesyanzhinov V.V., Kurochkina L.P., Hawkins R.E. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4:1997;1004-1012.
72. Kawamoto T., Sato J.D., Le A., Polikoff J., Sato G.H. et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA. 80:1983;1337-1341.
73. Michael S.I., Hong J.S., Curiel D.T., Engler J.A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 2:1995;660-668.
74. Moody T.W., Bertness V., Carney D.N. Bombesin-like peptides and receptors in human tumor cell lines. Peptides. 4:1983;683-686.
75. Krasnykh V.N., Mikheeva G.V., Douglas J.T., Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 70:1996;6839-6846.
76. Stevenson S.C., Rollence M., Marshall Neff J., McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol. 71:1997;4782-4790.
77. Zhang Y., Mukhopadhyay T., Donehower L.A., Georges R.N., Roth J.A. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther. 4:1993;451-460.
78. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 3:1997;639-645.
79. Goodrum F.D., Ornelles D.A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol. 72:1998;9479-9490.
80. Hall A.R., Dix B.R., O'Carroll S.J., Braithwaite A.W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med. 4:1998;1068-1072.
81. Blackwood E.M., Kadonaga J.T. Going the distance: a current view of enhancer action. Science. 281:1998;61-63.
82. Shinkai T., Saijo N., Tominaga K., Eguchi K., Shimizu E., Sasaki Y. et al. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer. 57:1986;1318-1323.
83. Schrewe H., Thompson J., Bona M., Hefta L.J., Maruya A., Hassauer M. et al. Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol. 10:1990;2738-2748.
84. Osaki T., Tanio Y., Tachibana I., Hosoe S., Kumagai T., Kawase I. et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54:1994;5258-5261.
85. Smith M.J., Rousculp M.D., Goldsmith K.T., Curiel D.T., Garver R.I. Jr Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum Gene Ther. 5:1994;29-35.
86. Broers J.L.V., Jensen S.M., Travis W.D., Pass H., Whitsett J.A., Singh G. et al. Expression of surfactant associated protein-A and clara cell 10 kilodalton mRNA in neoplastic and non-neoplastic human lung tissue as detected by in situ hybridization. Lab Invest. 66:1992;337-346.
87. Strayer M.S., Guttentag S.H., Ballard P.L. Targeting type II and Clara cells for adenovirus-mediated gene transfer using the surfactant protein B promoter. Am J Respir Cell Mol Biol. 18:1998;1-11.
88. Eisenberg S.P., Coen D.M., McKnight S.L. Promoter domains required for expression of plasmid-borne copies of the herpes simplex virus thymidine kinase gene in virus-infected mouse fibroblasts and microinjected frog oocytes. Mol Cell Biol. 5:1985;1940-1947.
89. Forss Petter S., Danielson P.E., Catsicas S., Battenberg E., Price J., Nerenberg M. et al. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron. 5:1990;187-197.
90. Roemer K., Johnson P.A., Friedmann T. Transduction of foreign regulatory sequences by a replication-defective herpes simplex virus type 1: the rat neuron-specific enolase promoter. Virus Res. 35:1995;81-89.
91. Higashiyama M., Doi O., Kodama K., Yokouchi H., Tateishi R. Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology. 51:1994;544-551.
92. Shimizu E., Coxon A., Otterson G.A., Steinberg S.M., Kratzke R.A., Kim Y.W. et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 9:1994;2441-2448.
93. D'Amico D., Carbone D., Mitsudomi T., Nau M., Fedorko J., Russell E. et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene. 7:1992;339-346.
94. Takahashi T., Suzuki H., Hida T., Sekido Y., Ariyoshi Y., Ueda R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 6:1991;1775-1778.
95. Rodenhuis S., Slebos R.J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 52:1992;2665s-2669s.
96. Mitsudomi T., Viallet J., Mulshine J.L., Linnoila R.I., Minna J.D., Gazdar A.F. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 6:1991;1353-1362.
97. Shapiro G.I., Edwards C.D., Kobzik L., Godleski J., Richards W., Sugarbaker D.J. et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 55:1995;505-509.
98. Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T. et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53:1993;1-4.
99. Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S. et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 7:1992;171-180.